322 related articles for article (PubMed ID: 29590065)
1. Beyond PARP-POLθ as an anticancer target.
Higgins GS; Boulton SJ
Science; 2018 Mar; 359(6381):1217-1218. PubMed ID: 29590065
[No Abstract] [Full Text] [Related]
2. Poly(ADP) ribose polymerase promotes DNA polymerase theta-mediated end joining by activation of end resection.
Luedeman ME; Stroik S; Feng W; Luthman AJ; Gupta GP; Ramsden DA
Nat Commun; 2022 Aug; 13(1):4547. PubMed ID: 35927262
[TBL] [Abstract][Full Text] [Related]
3. Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair.
Ceccaldi R; Liu JC; Amunugama R; Hajdu I; Primack B; Petalcorin MI; O'Connor KW; Konstantinopoulos PA; Elledge SJ; Boulton SJ; Yusufzai T; D'Andrea AD
Nature; 2015 Feb; 518(7538):258-62. PubMed ID: 25642963
[TBL] [Abstract][Full Text] [Related]
4. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
5. Polymerase θ Coordinates Multiple Intrinsic Enzymatic Activities during DNA Repair.
Zahn KE; Jensen RB
Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573292
[TBL] [Abstract][Full Text] [Related]
6. DNA polymerase theta (Polθ) - an error-prone polymerase necessary for genome stability.
Brambati A; Barry RM; Sfeir A
Curr Opin Genet Dev; 2020 Feb; 60():119-126. PubMed ID: 32302896
[TBL] [Abstract][Full Text] [Related]
7. Leveraging DNA repair deficiency in gynecologic oncology.
Walsh CS; Hodeib M
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):24-31. PubMed ID: 26694829
[TBL] [Abstract][Full Text] [Related]
8. Molecular pathways: targeting PARP in cancer treatment.
Do K; Chen AP
Clin Cancer Res; 2013 Mar; 19(5):977-84. PubMed ID: 23269547
[TBL] [Abstract][Full Text] [Related]
9. PARP Inhibitors: The Cornerstone of DNA Repair-Targeted Therapies.
del Rivero J; Kohn EC
Oncology (Williston Park); 2017 Apr; 31(4):265-73. PubMed ID: 28412778
[TBL] [Abstract][Full Text] [Related]
10. [Cancer therapy by PARP inhibitors].
Seimiya H
Nihon Rinsho; 2015 Aug; 73(8):1330-5. PubMed ID: 26281686
[TBL] [Abstract][Full Text] [Related]
11. Biomarker-Guided Development of DNA Repair Inhibitors.
Cleary JM; Aguirre AJ; Shapiro GI; D'Andrea AD
Mol Cell; 2020 Jun; 78(6):1070-1085. PubMed ID: 32459988
[TBL] [Abstract][Full Text] [Related]
12. Mammalian polymerase θ promotes alternative NHEJ and suppresses recombination.
Mateos-Gomez PA; Gong F; Nair N; Miller KM; Lazzerini-Denchi E; Sfeir A
Nature; 2015 Feb; 518(7538):254-7. PubMed ID: 25642960
[TBL] [Abstract][Full Text] [Related]
13. Gynecologic Cancers: Emerging Novel Strategies for Targeting DNA Repair Deficiency.
Kristeleit RS; Miller RE; Kohn EC
Am Soc Clin Oncol Educ Book; 2016; 35():e259-68. PubMed ID: 27249731
[TBL] [Abstract][Full Text] [Related]
14. PARP inhibitors: its role in treatment of cancer.
Chen A
Chin J Cancer; 2011 Jul; 30(7):463-71. PubMed ID: 21718592
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in cancer therapy using PARP inhibitors.
Kaur SD; Chellappan DK; Aljabali AA; Tambuwala M; Dua K; Kapoor DN
Med Oncol; 2022 Sep; 39(12):241. PubMed ID: 36180646
[TBL] [Abstract][Full Text] [Related]
16. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.
Ashworth A
J Clin Oncol; 2008 Aug; 26(22):3785-90. PubMed ID: 18591545
[TBL] [Abstract][Full Text] [Related]
17. [Poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 cancer therapy].
Kluzek K; Białkowska A; Koczorowska A; Zdzienicka MZ
Postepy Hig Med Dosw (Online); 2012 Jun; 66():372-84. PubMed ID: 22706123
[TBL] [Abstract][Full Text] [Related]
18. Targeting backup DNA repair in cancer.
Cancer Discov; 2015 Jun; 5(6):OF7. PubMed ID: 25851856
[TBL] [Abstract][Full Text] [Related]
19. [PARP inhibitors--theoretical basis and clinical application].
Dębska S; Kubicka J; Czyżykowski R; Habib M; Potemski P
Postepy Hig Med Dosw (Online); 2012 May; 66():311-21. PubMed ID: 22706117
[TBL] [Abstract][Full Text] [Related]
20. DNA double strand break repair defect and sensitivity to poly ADP-ribose polymerase (PARP) inhibition in human papillomavirus 16-positive head and neck squamous cell carcinoma.
Weaver AN; Cooper TS; Rodriguez M; Trummell HQ; Bonner JA; Rosenthal EL; Yang ES
Oncotarget; 2015 Sep; 6(29):26995-7007. PubMed ID: 26336991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
